HIV/HBV共感染患者抗HBV药物治疗

Anti-HBV therapy for HIV/HBV co-infected patients

据报道,HIV感染人群中慢性乙肝患者的比例为4%～10%,HIV病毒感染增加了慢性乙肝患者发生肝纤维化和终末期肝病的风险。因此,对HIV/HBV共感染者需采取更有效的措施进行治疗。HBV抗病毒治疗的目标是抑制乙肝病毒复制、阻止疾病进展,减少HBV相关的致病性和致死率。目前HBV抗病毒治疗药物如INF-α、拉米夫定或恩曲他滨、恩替卡韦、替比夫定、阿德福韦、替诺福韦均具有不同程度的抗HIV病毒的作用,单药使用虽可有效的抗HBV病毒,但可能均不同程度地导致HIV病毒变异。

It is reported that 4-10% of HIV-infected patients have chronic hepatitis B, and HIV increases the risk of cirrhosis and end-stage liver disease in HBV co-infection, which indicates more effective regimens should be taken for treatment of HIV/HBV co-infection. The goal of HIV/HBV co-infection is to suppress HBV viral replication, minimize ongoing hepatic damage, and reduce the morbidity and mortality. Some drugs such as a-interferon, tenofovir, telbivudine, lamivudine, emtricitabine, entecavir, or adefovir are active against HBV but with weak anti-HIV activity.